SEARCH

SEARCH BY CITATION

References

  • 1
    Barentsen R, Groeneveld FPMJ, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 203207.
  • 2
    Mitchell A, Walsh D, Hart DM. Induced menstruation and cyclical opposed oestrogen replacement therapy: a survey of patient attitudes. Sixth International Congress on the Menopause; 1990 Oct, Bangkok , Thailand . Abstract 252.
  • 3
    Perry W, Wiseman RA, Cullen NM. Combined oral oestradiol valerate- norethisterone treatment over three years in postmenopausal women. 1. Clinical aspects and endometrial histology. Gynecol Endocrinol 1998; 12: 109122.
  • 4
    Christiansen C, Riis BJ. 17-β oestradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836841.
  • 5
    Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone-turnover to hormone replacement therapy: Impact of biological variability. J Bone Min Res 1998; 13: 11241133.
  • 6
    Christiansen C, Christiansen MS, Transol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1: 459461.
  • 7
    Munk-Jensen N, Nielson SP, Obel EB, Erikson PB. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. BMJ 1988; 296: 11501152.
  • 8
    Schneider HPG, Dören M. Oestrogen-progestogen replacement therapies in pre- and postmenopausal women—prevention of osteoporosis. In: ChristiansenC, PeckWA, RiisBJ, editors. Proceedings of Osteoporosis Symposium, 1989 JuneJuly, Copenhagen , Denmark . Handelstrykkeriet Aalborg ApS, Aalborg. 1989; 4953
  • 9
    Mazess RB, Barden HS, Ettinger M et al. Spine and femur density using dual photon absorptiometry in US white women. Bone and Mineral 1987; 2: 211219.
  • 10
    Christiansen C, Nilas L, Riis BJ, Redbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985; 2: 800801.
  • 11
    Stepan JJ, Pospichal J, Schreiber V, Kanka J, Presl J, Pacovsky V. Evidence that the progestational agent norethisterone protects against menopausal bone loss. In: ChristiansenC, OvergaardK, editors. Third International Symposium on Osteoporosis 1990 Oct 1418, Copenhagen , Denmark . Handelstrykkeriet Aalborg, ApS, Aalborg, 1990; 2: 10121014.
  • 12
    Stevenson JC, Lees B, Devenport M, Cust RP, Ganger KF. Determinates of bone density in normal women: Risk factors for future osteoporosis BMJ 1989; 298: 924928.
  • 13
    Perry W, Anderson M, Mortimer C. Osteoporosis in a largely self-referred population: high prevalence but low medical priority. Why Miner Electrolyte Metabol 1994; 20: 287293.